Dow Jones 10831.19 +64.96 9:14 am PST, March 1, 2005  NASDAQ 2065.50 +13.78 For info, visit access.smallcapnetwork.com S & P 500 1210.23 +6.63 Change your subscription status here Russell 2000 637.30 +3.24 VOLUME 05: ISSUE 16  Feature: Biocurex Rising. Company Updates. As we noted on the SCBLOG over the weekend, there appears to be something going on with the shares of Biocurex (BOCX.PK). Friday, the shares closed at $1.15, after closing at 76 cents, Thursday. Friday's volume was north of 800,000 shares. On Monday the shares eased slightly and closed at 97 cents on trading of over 400,000 shares. The company issued an update (http://biz.yahoo.com/pz/050225/73436.html), after the close, Friday.  Within that release, Biocurex noted that it is progressing with it's licensing negotiations as well as continuing efforts to return its shares to the OTCBB from the Pink Sheets where it has traded for the last few months. Risk-oriented investors should begin or continue to accumulate Biocurex at these levels with an eye to buying on dips, should they occur. The shares executed a good technical retracement, Monday, after Friday's run to $1.25. Once the shares hit the 88-cent level, Monday, they reversed direction and moved up to close at 97 cents. It appears from the trading action that the next chart resistance point kicks in at the $1.44 level.  Volatility is certainly no stranger to the shares of Biocurex. Since we alerted the readership to the company in October, 2003 at 17 cents, the shares subsequently shot up to $3.90 in early 2004--prior to the peak we made a partial sell suggestion as the shares crossed $2-plus.  A few weeks later the shares were halted by the SEC to address questions the regulator had regarding some of the company's claims. The company has and continues to cooperate fully with the SEC to resolve the matter. In May 2004 the shares were moved to the Pink Sheets in accordance with NASD rules. Pushing Forward. As we have said before, even though faced with these challenges, Biocurex continues its important work and, over the balance of 2004, produced impressive refinements and results for its proprietary RECAF ? blood and tissue tests, both in-house and with external partners. On November 30th, for example, we published a piece on the developments on Biocurex's RECAF ? blood test as it applied to the detection of prostate cancer and its apparent superiority over the standard PSA test.  The company has steadily built an impressive list of product results and while still in its formative stage, management has continued to drive forward both with R&D, exposing it's technology to potential partners and licensees, as well as continuing licensing discussions with appropriate third parties. The Bottomline? Biocurex is an extremely interesting company with, we believe, compelling potential. It has something for everyone, whether trader or long-term investor. For both, we believe a core position at these levels in the long-term end of the speculative portion of a portfolio makes sense. We further feel that patience has and will be rewarded as the company moves toward commercialization, continues licensing discussions and develops new products while refining its current offerings. Obviously, we will continue to bring you news and our take on Biocurex if, as, and when, the company makes further announcements.     We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130   Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.